EQPT LAWSUIT: EquipmentShare.com Inc. Sued for Securities Law Violations; Investors Should Contact Block & Leviton To Learn How They Might Recover Their Losses

EquipmentShare.com Inc. (EQPT) faces a securities fraud lawsuit after allegedly making false statements about terminating related-party transactions with founder-controlled entities. A short-seller report revealed undisclosed transactions netting founders at least $77 million, causing the stock to plummet 34.5% below its IPO price. Investors who purchased shares between January 23 and June 23, 2026, may be eligible to recover losses.

07/24/2026, 7:45 AM • GlobeNewswire

Immix Biopharma Investigated by the Portnoy Law Firm

The Portnoy Law Firm has launched an investigation into possible securities fraud at Immix Biopharma after discovering that an executive operating under the alias 'Richard Graydon' was actually Ronald Fischer, a fugitive wanted in Rhode Island. The company terminated the officer on July 17, 2026, claiming the separation was unrelated to his activities. Following the disclosure, Immix's stock price declined approximately 10.83%.

07/21/2026, 1:51 PM • GlobeNewswire

IMMX ALERT: Immix Biopharma Investigated for Securities Fraud Violations by Block & Leviton; Investors Should Contact the Firm

Block & Leviton is investigating Immix Biopharma for potential securities law violations after discovering that an executive operating under the name 'Richard Graydon' was actually a Rhode Island fugitive named Ronald Fischer using a false identity. The company terminated the individual on July 17, 2026, stating it was unrelated to his work activities. Immix shares fell approximately 10.83% following the news report.

07/20/2026, 11:47 AM • GlobeNewswire

Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock

Immix Biopharma closed an underwritten registered offering of 16.78 million shares at $8.94 per share, raising approximately $140.65 million in net proceeds. The financing was led by Morgan Stanley and BofA Securities, with participation from leading U.S. biotechnology institutional investors and mutual funds.

05/22/2026, 5:15 PM • GlobeNewswire

Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2

Immix Biopharma reported a 95% complete response rate (19 of 20 patients) in its NEXICART-2 Phase 2 trial for relapsed/refractory AL Amyloidosis using its CAR-T therapy NXC-201. All four MRD-negative patients from ASH 2025 converted to complete response, with no relapses observed to date. The company plans to initiate a Phase 3 trial in newly diagnosed patients and expects BLA submission by end of March 2027.

05/21/2026, 6:00 AM • GlobeNewswire

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Immix Biopharma successfully closed a $100 million public offering of common stock and pre-funded warrants, raising approximately $93.7 million with support from leading biotechnology institutional investors and mutual funds.

12/09/2025, 5:45 PM • GlobeNewswire

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Immix Biopharma priced an underwritten offering of common stock and pre-funded warrants, expecting to raise $100 million to fund NXC-201 development and corporate operations through mid-2027.

12/07/2025, 6:20 PM • GlobeNewswire

At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

Immix Biopharma announced promising Phase 2 clinical trial results for NXC-201, a CAR-T cell therapy targeting relapsed/refractory AL Amyloidosis, with a 75% complete response rate and potential to increase to 95%.

12/07/2025, 6:15 PM • GlobeNewswire